Javascript must be enabled to continue!
THALIDOMIDE AND PHOCOMELIA
View through CrossRef
THALIDOMIDE [alpha (N-phthalimido) glutarimide] is a synthetic drug with the structural formula shown in Figure 1. Thalidomide was invented by the firm of Chemie Grünenthal as a sedative, but when tested on animals was found to be ineffective. Chemie Grünenthal was, however, so certain that thalidomide must have some quieting effect on the central nervous system that it was then tested on man for its effect on epilepsy, and promptly reported to be useless as an anti-convulsant but an excellent sedative. By 1957, thalidomide, marketed under the trade-name of Contergan, was widely used as a sedative and for mental patients. It was considered "safe" to keep in the home because an overdose caused a sound sleep but never produced fatal poisoning. Thalidomide was added to other preparations for conditions where sedation would be beneficial, such as headaches (Algosedive, which is aspirin, phenacetin, and thalidomine), migraine, cough, asthma, gastrointestinal disturbances, grippe, arthralgia, and arthritis. A preparation with a small amount of thalidomide was sold as a tranquilizer.
The rights to market the drug were sold to a number of foreign pharmaceutical firms, and the drug was exported to many other countries. Thus, to my certain knowledge, more than a dozen preparations have been placed on the market in a minimum of 16 countries, excluding the United States, where it was distributed to over 1,000 physicians for investigation. Table I gives a list of these drugs which the author has been able to check. Evidence is steadily accumulating which indicates that both the number of preparations and the number of countries is far in excess of the above figures.
Title: THALIDOMIDE AND PHOCOMELIA
Description:
THALIDOMIDE [alpha (N-phthalimido) glutarimide] is a synthetic drug with the structural formula shown in Figure 1.
Thalidomide was invented by the firm of Chemie Grünenthal as a sedative, but when tested on animals was found to be ineffective.
Chemie Grünenthal was, however, so certain that thalidomide must have some quieting effect on the central nervous system that it was then tested on man for its effect on epilepsy, and promptly reported to be useless as an anti-convulsant but an excellent sedative.
By 1957, thalidomide, marketed under the trade-name of Contergan, was widely used as a sedative and for mental patients.
It was considered "safe" to keep in the home because an overdose caused a sound sleep but never produced fatal poisoning.
Thalidomide was added to other preparations for conditions where sedation would be beneficial, such as headaches (Algosedive, which is aspirin, phenacetin, and thalidomine), migraine, cough, asthma, gastrointestinal disturbances, grippe, arthralgia, and arthritis.
A preparation with a small amount of thalidomide was sold as a tranquilizer.
The rights to market the drug were sold to a number of foreign pharmaceutical firms, and the drug was exported to many other countries.
Thus, to my certain knowledge, more than a dozen preparations have been placed on the market in a minimum of 16 countries, excluding the United States, where it was distributed to over 1,000 physicians for investigation.
Table I gives a list of these drugs which the author has been able to check.
Evidence is steadily accumulating which indicates that both the number of preparations and the number of countries is far in excess of the above figures.
Related Results
P25 Thalidomide administration through a nasogastric tube
P25 Thalidomide administration through a nasogastric tube
IntroductionLA, 15 year old female diagnosed with tuberculosis meningitis (TBM). General paediatric team recommended, in combination with existing adjunctive therapy, initiation of...
A combined case of amelia and phocomelia in a neonate, at JFK Maternity Center, Liberia
A combined case of amelia and phocomelia in a neonate, at JFK Maternity Center, Liberia
We report a case of spontaneous rare birth deformity. A case of Amelia and Phocomelia in a neonate. Amelia is a rare congenital disorder, even more so, is the combined amelia and p...
An in-depth review of thalidomide's basic moieties
An in-depth review of thalidomide's basic moieties
Thalidomide, also referred to as N-phthalimido glutarimide, was initially made available as a sedative by Chemie Grunelthal GmbH in West Germany in 1957. Thalidomide's chemical str...
Role of thalidomide in angiodysplasia-related gastrointestinal bleeding: a systematic review
Role of thalidomide in angiodysplasia-related gastrointestinal bleeding: a systematic review
Objective
Angiodysplasia of the gastrointestinal (GI) tract is a leading cause of occult GI bleeding, and its management remains challenging. Various pharmacolo...
Thalidomide use in dermatological diseases in Brazil
Thalidomide use in dermatological diseases in Brazil
Abstract
This prospective study on the use of thalidomide in dermatological diseases was conducted at the Dermatology Outpatient Clinic of the ABC Medical School and its ma...
UNILATERAL LOWER LIMB PHOCOMELIA DURING THE COVID-19 PANDEMIC: ETHICAL DILEMMA FROM AN OBSTETRICIAN’S PERSPECTIVE
UNILATERAL LOWER LIMB PHOCOMELIA DURING THE COVID-19 PANDEMIC: ETHICAL DILEMMA FROM AN OBSTETRICIAN’S PERSPECTIVE
Isolated unilateral phocomelia is a rare congenital disorder. Historically, the most famous association with consumption of thalidomide in first trimester of pregnancy resulted in ...
Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model
Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model
AbstractThalidomide is a teratogen in humans but not in rodents. It causes multiple birth defects including malformations of limbs, ears, and other organs. However, the species-spe...
Reduction in peripapillary retinal thickness after Thalidomide Treatment in Patients with POEMS Syndrome
Reduction in peripapillary retinal thickness after Thalidomide Treatment in Patients with POEMS Syndrome
PurposeTo determine whether thalidomide treatment can reduce the optic disc edema in patients with the polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin...

